Efficacy of Kan Jang<sup>®</sup> in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial

Efficacy of Kan Jang<sup>®</sup> in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial

Kan Jang<sup>®</sup>, the fixed combination of <i>Andrographis paniculata</i> (Burm. F.) Wall. ex. Nees and <i>Eleutherococcus senticosus</i> (Rupr. & Maxim.) Maxim extracts, is a herbal medicinal product for relieving symptoms of upper respiratory tract infec...

Full description

Bibliographic Details
Main Authors: Levan Ratiani, Elene Pachkoria, Nato Mamageishvili, Ramaz Shengelia, Areg Hovhannisyan, Alexander Panossian
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceuticals
Subjects:
adaptogens
Kan Jang<sup>®</sup>
<i>Andrographis paniculata</i>
<i>Eleutherococcus senticosus</i>
clinical trial
mild COVID-19
Online Access:https://www.mdpi.com/1424-8247/15/8/1013

Internet

https://www.mdpi.com/1424-8247/15/8/1013

Similar Items